NKTR — NEKTAR THERAPEUTICS
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 906709 ·
Last close
$60.92
Market Cap
$2.06B
52W High
$109.00
52W Low
$54.13
ADV30
926,911
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 10,861,000 | — | -38,258,000 | -44,904,000 | 763,271,000 | 149,578,000 | 187,055,000 |
| Dec 2025 | 21,807,000 | 21,807,000 | -19,090,000 | -36,079,000 | 280,406,000 | 15,116,000 | 190,574,000 |
| Sep 2025 | 11,790,000 | 11,790,000 | -31,532,000 | -35,522,000 | 301,347,000 | 41,032,000 | 216,261,000 |
| Jun 2025 | 11,175,000 | 11,175,000 | -35,783,000 | -41,593,000 | 207,534,000 | 42,988,000 | 231,745,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-208,511,000
Investing CF
$-1,197,000
Financing CF
$180,566,000
CapEx
$-171,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-10.20
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-3,760,286,000
Inventory
—
Receivables
$1,779,000
ST Investments
$230,636,000
EBIT TTM
$-129,303,000
Pretax Income TTM
$-155,487,000
Interest Exp TTM
$26,184,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$55,633,000
EBITDA
$-123,912,000
Free Cash Flow
$-107,228,376
Enterprise Value
$1,611,112,192
Total Cash
$568,604,032
Total Debt
$143,432,000
Shares Out
33,786,032
Trailing EPS
$-7.93
Book Value
$19.55
ROE
-53.6%
ROA
-15.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 55,232,000 | -130,771,000 | -164,076,000 | 280,406,000 | 190,574,000 | — | -208,511,000 |
| Dec 2024 | 98,427,000 | -129,918,000 | -118,961,000 | 303,850,000 | 243,113,000 | — | -175,709,000 |
| Dec 2023 | 90,122,000 | -135,225,000 | -276,056,000 | 398,033,000 | 267,046,000 | — | -192,606,000 |
| Dec 2022 | 92,055,000 | -240,236,000 | -368,198,000 | 710,600,000 | 343,962,000 | — | -304,007,000 |
TTM Snapshot
Revenues TTM
$105,757,000
NetIncome TTM
$-495,945,000
OpCashFlow TTM
$0
Assets (Latest)
$710,600,000
Forward EPS
$-12.56
Max Pain — expiry 2026-07-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $70.00 · spot: $60.92 · call volume: 1,122 · put volume: 841
Expected Move to 2026-07-17:
±$9.00
(14.77%) —
implied range
$51.92 –
$69.92
· ATM straddle on $60.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BHVN | Biohaven Ltd. | $2.05B | $13.62 | — |
| AUPH | Aurinia Pharmaceuticals Inc. | $2.08B | $16.14 | — |
| IMNM | Immunome Inc. | $2.10B | $18.53 | — |
| ZLAB | Zai Lab Ltd | $2.01B | $17.88 | — |
| OCUL | OCULAR THERAPEUTIX, INC | $2.11B | $9.64 | — |
News headlines (Yahoo Finance, 1h cache)
A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Volatility
2026-06-07 03:10 · Yahoo
What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock
2026-06-05 15:55 · Yahoo
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-03 20:15 · Yahoo
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
2026-05-27 22:00 · Yahoo
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch
2026-05-23 20:48 · Yahoo
This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%
2026-05-23 20:37 · Yahoo
Assessing Nektar Therapeutics (NKTR) Valuation After Strong REZPEG Prospects And Recent Share Price Momentum
2026-05-13 00:26 · Yahoo
Nektar Therapeutics Q1 2026 Earnings Call Summary
2026-05-08 12:30 · Yahoo
Nektar Therapeutics Q1 Earnings Call Highlights
2026-05-08 11:07 · Yahoo
Nektar (NKTR) Q1 2026 Earnings Transcript
2026-05-07 22:53 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.